FDA cancels adcomm in 'positive' sign for Exelixis’ Cabometyx bid in neuroendocrine tumors: analyst

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting.

Exelixis disclosed the cancellation Thursday while confirming that the FDA's original April 3 target decision date for the filing remains.